Phase I trial evaluating the safety of PKal inhibitor THR-149 for treating DME fully enrolled
THR-149 is a plasma kallikrein (PKal) inhibitor for treatment of DME. Through the inhibition of the plasma kallikrein-kinin (PKaI-kinin) system, THR-149 prevents the induction of retinal vascular permeability, inflammation and angiogenesis. Literature data show that patients with DME have elevated levels of plasma kallikrein and that the vitreous level of plasma kallikrein varies less compared to VEGF, making it a potentially more effective target for treating DME. Oxurion has reached full enrollment for the Phase I clinical study evaluating THR-149 for the treatment of DME.
We are pleased to announce that the Phase I trial for THR-149 is now fully enrolled. We are one step closer to assessing THR-149’s safety profile and its potential role in treating DME.
- Andy De Deene, MD, Global Head of Development
Clinical study evaluating THR-149 (a PKal inhibitor) for treatment of diabetic macular edema (DME)
Ongoing, fully enrolled
The THR-149-001 open-label, multicenter, dose escalation phase I clinical study (THR-149-001) assesses the safety of a single intravitreal injection of escalating dose levels of THR-149 in patients with DME. A total of 15 patient have been recruited.
Initial results from the THR-149-001 study are anticipated by Q3 2019.
Preclinical studies on bicyclic peptide inhibitors of PKal, such as THR-149, including those published in The Journal of Medicinal Chemistry in March, have demonstrated nanomolar to picomolar potencies, and stability in biological matrices and reported prolonged retention in the eye together with in vivo efficacy in diabetic models of retinal vascular permeability. These outcomes support THR-149’s development as a possible treatment for DME and DR via a VEGF-independent mechanism of action.